

UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

Office of the Director
Bureau of Competition

November 7, 2023

By Federal Express

NDA	Product Number	Product	Patent Number	Listing Type
-----	----------------	---------	---------------	--------------

We have opted to use the FDA's regulatory dispute process to address the improper listings, but we retain the right to take any further action the public interest may require, which may include investigating this conduct as an unfair method of competition under Section 5 of the FTC Act, 15 U.S.C. § 45, and as described in the Policy Statement.

Sincerely,

Rahul Rao
Deputy Director
Bureau of Competition

cc: Brian Savage
General Counsel
Teva Pharmaceuticals USA, Inc.,
400 Interpace Pkwy, Suite 3
Parsippany, NJ 07054
brian.savage@tevapharm.com

Enclosure: FTC Policy Statement Concerning Brand Drug Manufacturer Proper Listing of Patents in the Orange Book